ANNX

Annexon, Inc. operates as a clinical-stage biopharmaceutical company developing therapeutics for patients with classical complement-mediated autoimmune and neurodegenerative diseases. Headquartered in South San Francisco, California, the company focuses on discovering and developing novel therapies that target the classical complement pathway in the central nervous system and body. Annexon's lead product candidate, ANX005, is a monoclonal antibody designed to inhibit C1q, the initiating molecule of the classical complement pathway. The company advances this candidate through multiple clinical trials for indications including Guillain-Barré syndrome, warm autoimmune hemolytic anemia, and geographic atrophy secondary to age-related macular degeneration. Additionally, Annexon develops ANX007, an intravitreal anti-C1q antibody for ophthalmic disorders, and ANX1502, targeting the alternative complement pathway. Founded in 2011, the company completed its initial public offering in 2020. Annexon collaborates with academic institutions and research organizations to advance its understanding of complement biology and therapeutic applications. The company maintains research and development facilities in South San Francisco and employs approximately 130 people. Recent developments include releasing clinical trial data and expanding its pipeline to address additional complement-mediated conditions across neurology, hematology, and ophthalmology therapeutic areas.